As of July this year, based on Incyte's latest financial report, the company's current EPS (TTM) is $0.29. In 2024, INCY reported a per-share earnings of $0.16, which represents a decrease compared to the EPS of $2.67 recorded in 2023. Incyte's EPS for the quarterly period ending on Mar 31, 2025 was $0.82.
The yearly EPS in 2024 was $0.16, a decrease of 94% compared to $2.67 recorded in 2023. For the quarter ending Mar 31, 2025, the EPS was $0.82, reflecting a 7.9% increase compared to the same quarter a year earlier. The trailing twelve months (TTM) EPS as of March 2025 is $0.29. In 2023, the annual EPS was $2.67, showing an increase of 74.5% compared to 2022.
Incyte has recorded a growth in earnings per share of 7.9% over the past 12 months (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS annual growth rate of -66.6% per year for the last 3 years. Incyte had an average annual EPS growth of -40.1% over the last five years.
Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
---|---|---|---|---|
NVS Novartis AG | 17.03 | -17.2% | -17.9% | 2.9% |
PFE Pfizer Inc | 17.83 | 273.7% | -28.7% | -13.2% |
AMGN Amgen Inc | 27.74 | -39.3% | -9.7% | -10.1% |
LLY ELI LILLY & Co | 65.86 | 102.1% | 24.1% | 5.7% |
INCY Incyte Corp | 242.07 | -94% | -66.6% | -40.1% |
LGND Ligand Pharmaceuticals Inc | N/A | -107.3% | N/A | N/A |
ARDX Ardelyx Inc | N/A | 43.3% | N/A | N/A |
GERN Geron Corp | N/A | 15.6% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.